Episode Details
Back to EpisodesACR 2025: Mortality Risk With Belimumab and GLP-1 Agonists in Lupus and Lupus Nephritis
Episode 617
Published 5 months, 1 week ago
Description
Drs. Petri and Woolfson review the American College of Rheumatology Convergence 2025 data that suggest belimumab might lower mortality in SLE compared with traditional oral immunosuppressants, supporting earlier biologic use. They also discuss an observational study in lupus nephritis that links GLP-1 agonists to better kidney, survival, and cardiovascular outcomes than SGLT2 inhibitors, particularly in overweight patients.